News
Archives
- 2021
- 2020
- Oct (1)
- Jul (1)
- Apr (1)
- 2019
- Dec (1)
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2018
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
1 Jan 2014
4th Qtr 2013 New Site SIV and Site’s 1st Randomization in China
This last quarter has also seen the kick-off of Beijing Cancer Hospital and the Sun Yat Sen University Cancer Center. We congratulate Dr Huang I-Ping from Koo Foundation SYSCC, Dr Peng from Zhongshan City People’s Hospital and Prof Ding from 2nd affiliated Hospital of Zhejiang University for their first subjects recruited onto study last quarter. By the end of December, Zhongshan City People’s Hospital Team recruited 3 subjects and 2nd affiliated Hospital of Zhejiang University team recruited 9 subjects.